Baidu
map

Eur Radiol:冠心病患者福音--通过冠脉CTA随访预测远期风险!

2017-11-02 shaosai MedSci原创

本研究旨在利用冠状动脉CT血管造影(CCTA)评价稳定性心绞痛患者冠状动脉粥样硬化斑块负荷进展的预测价值,并探究其与主要心血管事件(MACE)发生率的相关性,并将结果发表在Eur Radiol上。

本研究旨在利用冠状动脉CT血管造影(CCTA)评价稳定性心绞痛患者冠状动脉粥样硬化斑块负荷进展的预测价值,并探究其与主要心血管事件(MACE)发生率的相关性,并将结果发表在Eur Radiol上。本研究回顾性分析了有稳定性心绞痛病史并因心绞痛复发或加重多次进行CCTA检查的患者。定量分析冠状动脉斑块脂质核、纤维帽、钙化、整体斑块负荷及管径狭窄。通过随访来评价MACE发生率。本研究共纳入了268例患者(平均年龄52.9 ± 9.8岁,男性占71%),并对其进行了平均约4.6 ± 0.9年的随访。有富脂质、纤维化、钙化、整体斑块负荷(%)进展及冠状动脉管径狭窄(%)进展的患者MACE发生率要明显高于无上述进展的患者(p均 < 0.05)。富脂质斑块(HR = 1.601, p = 0.021)、整体斑块负荷(HR = 2.979, p = 0.043)和冠状动脉管径狭窄(HR = 4.327, p <0.001)是预测MACE的独立预测因子。本研究表明,发生心绞痛复发或其他症状加重的冠心病患者在CCTA图像上会有冠状动脉硬化进展,这会增加患者未来发生MACE的风险。原始出处:G

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849559, encodeId=eac4184955933, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Aug 10 14:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055485, encodeId=018020554859f, content=<a href='/topic/show?id=ed25944312b' target=_blank style='color:#2F92EE;'>#远期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94431, encryptionId=ed25944312b, topicName=远期风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Oct 09 21:47:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447709, encodeId=3fe4144e7091f, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493771, encodeId=94671493e71e7, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630052, encodeId=cc7d16300527a, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2018-08-10 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849559, encodeId=eac4184955933, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Aug 10 14:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055485, encodeId=018020554859f, content=<a href='/topic/show?id=ed25944312b' target=_blank style='color:#2F92EE;'>#远期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94431, encryptionId=ed25944312b, topicName=远期风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Oct 09 21:47:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447709, encodeId=3fe4144e7091f, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493771, encodeId=94671493e71e7, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630052, encodeId=cc7d16300527a, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849559, encodeId=eac4184955933, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Aug 10 14:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055485, encodeId=018020554859f, content=<a href='/topic/show?id=ed25944312b' target=_blank style='color:#2F92EE;'>#远期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94431, encryptionId=ed25944312b, topicName=远期风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Oct 09 21:47:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447709, encodeId=3fe4144e7091f, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493771, encodeId=94671493e71e7, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630052, encodeId=cc7d16300527a, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849559, encodeId=eac4184955933, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Aug 10 14:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055485, encodeId=018020554859f, content=<a href='/topic/show?id=ed25944312b' target=_blank style='color:#2F92EE;'>#远期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94431, encryptionId=ed25944312b, topicName=远期风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Oct 09 21:47:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447709, encodeId=3fe4144e7091f, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493771, encodeId=94671493e71e7, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630052, encodeId=cc7d16300527a, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849559, encodeId=eac4184955933, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Aug 10 14:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055485, encodeId=018020554859f, content=<a href='/topic/show?id=ed25944312b' target=_blank style='color:#2F92EE;'>#远期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94431, encryptionId=ed25944312b, topicName=远期风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Oct 09 21:47:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447709, encodeId=3fe4144e7091f, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493771, encodeId=94671493e71e7, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630052, encodeId=cc7d16300527a, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Sat Nov 04 07:47:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2017-11-04 许安

相关资讯

JACC:研究表明,病情稳定的冠心病患者多活动有明显益处,平素不爱动者更要活动

近期发表在JACC上的STABILITY研究提示,对于稳定性冠心病患者来说,多运动有助于降低死亡风险。

血脂异常五问

动脉粥样硬化性心血管疾病,如冠状动脉粥样硬化性心脏病(冠心病)、脑血管病、下肢跛行等,是我国居民致死致残的主要原因,血脂异常是导致此类疾病的重要危险因素之一。有效防治心脑血管疾病,除了积极改变不良生活习惯、积极防控高血压和高血糖之外,还应充分重视对血脂异常的防治。今天我们来谈谈血脂相关的几个常见基础问题。

超全总结,冠心病抗栓遭遇消化道出血怎么治?

冠心病患者抗栓治疗中如何评估消化道出血风险?在冠心病抗栓治疗中出现消化道出血患者应该如何调整抗栓策略?

SCI REP:冠心病筛查中餐后血糖由于空腹血糖和糖化血红蛋白!

在中国人群中,冠心病的严重程度与血糖有关,而不是胰岛素抵抗。PBG与冠心病的存在和严重程度呈正相关。

Lancet:药物洗脱支架用于75岁以上老年冠心病患者效果优于裸金属支架

研究认为,对于接受经皮冠状动脉介入的75岁以上患者,药物洗脱支架联合短期双联抗血小板治疗相比裸金属支架联合短期双联抗血小板治疗,可降低患者全因死亡、心肌梗死、中风与缺血驱动的靶病变血运重建的发生率,同时药物洗脱支架联合短期双联抗血小板治疗可降低PCI后老年患者的出血风险

JACC:脂蛋白的糖基化水平会影响T2DM患者的冠心病发生

脂蛋白的非酶糖基化作用在糖尿病患者血管并发症的发生过程中起到重要作用。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估2型糖尿病(T2DM)患者的脂蛋白(apo)A-IV是否存在糖基化,并且apoA-IV的糖基化是否与冠心病(CAD)的发生有关的临床研究。本研究纳入了204名不伴有CAD的T2DM患者(第一组),515名伴有CAD的T2DM患者(第二组)和176名正常对照。apoA-IV是从

Baidu
map
Baidu
map
Baidu
map